Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 08/20 05:35:08 pm
78.54 EUR   +0.80%
08/17UCB : Transparency notification BlackRock, Inc
AQ
08/16UCB : Transparency notification BlackRock, Inc.
PU
08/16UCB : Threshold crossings
CO
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Most relevant news about UCB
08/17UCB : Transparency notification BlackRock, Inc
AQ
08/16UCB : Transparency notification BlackRock, Inc.
PU
08/16UCB : Threshold crossings
CO
08/10UCB : Transparency notification BlackRock, Inc.
PU
08/10UCB : Threshold crossings
CO
08/08UCB : Transparency notifications BlackRock, Inc.
PU
08/08UCB : Threshold crossings
CO
08/03UCB : Transparency notifications BlackRock, Inc.
PU
08/03UCB : Threshold crossings
CO
07/26UCB : S.A. - Transparency notifications BlackRock, Inc
AQ
07/26UCB : Half-year results
CO
07/24UCB : Transparency notifications BlackRock, Inc.
PU
07/17UCB : Transparency notification
AQ
07/17UCB : and Amgen Resubmit Biologics Licence Application for EVENITYTM to the U.S...
AQ
07/13ICER panel votes against elagolix for endometriosis
AQ
More most relevant news
All news about UCB
08/17UCB : Transparency notification BlackRock, Inc
AQ
08/16UCB : Transparency notification BlackRock, Inc.
PU
08/16UCB : Threshold crossings
CO
08/10UCB : Transparency notification BlackRock, Inc.
PU
08/10UCB : Threshold crossings
CO
08/09UCB : "Method And System For Predicting Optimal Epilepsy Treatment Regimes" in P..
AQ
08/08UCB : Transparency notifications BlackRock, Inc.
PU
08/08UCB : Threshold crossings
CO
08/03UCB : Transparency notifications BlackRock, Inc.
PU
08/03UCB : Threshold crossings
CO
More news
Sector news : Pharmaceuticals - NEC
08/20EUROPE MARKETS: Bayer And Oil Shares Lead Gains For European Stock Benchmarks
DJ
08/20ALEXION : FDA Accepts Priority Review of ALXN1210 in Blood Disorder
DJ
08/20ROCHE : Alecensa latest beneficiary of faster China drug approvals
RE
08/20Roche's Alecensa Gets Green Light From China National Drug Administration
DJ
08/18ASTRAZENECA : Biopharma Spinout Entasis Files for IPO
DJ
08/17BAYER : Rejects Media Report of Fresh Dicamba Lawsuits
DJ
More sector news : Pharmaceuticals - NEC
Official Publications
08/16Threshold crossings 
08/10Threshold crossings 
08/08Threshold crossings 
08/03Threshold crossings 
07/26Half-year results 
07/06Crossing thresholds 
More official Publications
News from SeekingAlpha
08/14YOUR DAILY PHARMA SCOOP : Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA.. 
08/13FDA accepts UCB's marketing application for midazolam nasal spray for seizure.. 
07/26UCB S.A. ADR 2018 Q2 - Results - Earnings Call Slides 
07/13Amgen resubmits U.S. marketing application for osteoporosis med Evenity 
06/01EMA advisory group backs expanded use for UCB's Briviact 
05/17YOUR DAILY PHARMA SCOOP : Loxo Outstanding Results, Cimzia Trial Success, Audent.. 
Latest Tweets
08/16UCB : Transparency notification BlackRock, Inc.  
08/13"The Get Brown" at UCB uses sketch to goof on the comics' dual identities and..
2
08/08UCB : Transparency notifications BlackRock, Inc.  
08/05“It’s like that scene from Home Alone, except instead of cardboard cutouts, i..
1
08/03UCB : Transparency notifications BlackRock, Inc.  
More tweets
Qtime:61
Financials (€)
Sales 2018 4 564 M
EBIT 2018 1 122 M
Net income 2018 764 M
Finance 2018 75,5 M
Yield 2018 1,61%
P/E ratio 2018 19,09
P/E ratio 2019 17,61
EV / Sales 2018 3,29x
EV / Sales 2019 3,05x
Capitalization 15 074 M
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Average target price 69,6 €
Spread / Average Target -11%
EPS Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB18.68%17 334
JOHNSON & JOHNSON-3.76%360 750
PFIZER16.21%246 736
NOVARTIS0.10%211 093
ROCHE HOLDING LTD.-2.66%208 211
MERCK AND COMPANY24.70%183 667